IP Library Granted Patent US 6,867,248
Granted Patent B1
US 6,867,248 · App. 10/403,244 · Granted Mar 15, 2005

Polyhydroxyalkanoate compositions having controlled degradation rates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,867,248
App. No.
10/403,244
Granted
Mar 15, 2005
Kind
B1
Abstract

Biocompatible polyhydroxyalkanoate compositions with controlled degradation rates have been developed. In one embodiment, the polyhydroxyalkanoates contain additives to alter the degradation rates. In another embodiment, the polyhydroxyalkanoates are formed of mixtures of monomers or include pendant groups or modifications in their backbones to alter their degradation rates. In still another embodiment, the polyhydroxyalkanoates are chemically modified. Methods for manufacturing the devices which increase porosity or exposed surface area can be used to alter degradability. For example, as demonstrated by the examples, porous polyhydroxyalkanoates can be made using methods that creates pores, voids, or interstitial spacing, such as an emulsion or spray drying technique, or which incorporate leachable or lyophilizable particles within the polymer. Examples describe poly(4HB) compositions including foams, coatings, meshes, and microparticles. As demonstrated by the examples, these polyhydroxyalkanoate compositions have extremely favorable mechanical properties, as well as are biocompatible and degrade within desirable time frames under physiological conditions. These polyhydroxyalkanoate materials provide a wider range of polyhydroxyalkanoate degradation rates than are currently available. Methods for processing these materials, particularly for therapeutic, prophylactic or diagnostic applications, or into devices which can be implanted or injected, are also described.

Claims (4)

1. Methods for processing a biocompatible polyhydroxyalkanoate that has a controlled degradation rate under physiological conditions into a medical device

wherein the mass loss, as measured by gas chromatography, is greater than 5% over a six week period in vivo, or wherein the average molecular mass, as measured by gel permeation chromatography, decreases 20% to 50% over a ten week period in vivo.

2. The methods of claim 1 wherein the processing involves a process from the group consisting of solvent casting, melt processing, fiber processing, fiber spinning, fiber weaving, extrusion, injection molding, compression molding, lamination, and microparticle formation.

3. The method of claim 1 wherein the mass loss is from about 5% to about 75% over a six week period in vivo.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2016
From: METABOLIX, INC.
To: TEPHA, INC.
Reel/Frame 040283/0297 →
ADDRESS CHANGE Recorded May 2, 2016
From: METABOLIX, INC.
To: METABOLIX, INC.
Reel/Frame 038665/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2004
From: MARTIN, DAVID P.; SKRALY, FRANK; WILLIAMS, SIMON F.
To: METABOLIX, INC.
Reel/Frame 015368/0785 →